Moderna, Inc. (MRNA) Down 4.7% — Time to Fold This Position?
Moderna, Inc. (MRNA) gave back significant ground in Friday's session, declining 4.72% and shedding $2.69 to close at $54.33 on the NASDAQ. The drop pulls the stock further from its 52-week high of $85.60, reached on July 6, 2026—MRNA now sits approximately 36.5% below that peak, a reminder of how sharply the narrative has shifted since early July. At the other end of the range, the 52-week low of $22.28 provides a sobering reference point for just how volatile this stock has been over the past year.
Trading volume came in at approximately 2.9 million shares, running well below the 90-day average of roughly 7.2 million. The lighter-than-usual turnover on a down day suggests the selling was not panic-driven, but the absence of meaningful buying interest to absorb even modest pressure is a cautionary signal in its own right.
Why Moderna, Inc. Price is Moving Lower
Today's decline looks driven primarily by profit-taking and renewed valuation pressure, rather than any fresh clinical or regulatory setback—but that distinction offers limited comfort when the broader analyst picture is this bearish. With MRNA trading around $57 at the open and slipping to $54.33 by the close, the stock spent the entire session below its 50-day moving average of $58.42, a technically significant threshold that now represents near-term overhead resistance. The consensus analyst rating sits at "Reduce," with an average price target of roughly $40—a gap of more than $14 below today's close that makes it difficult to argue the stock is mispriced to the downside. Wolfe Research reinforced that skepticism on July 20, reiterating an "Underperform" rating with a $25 price target—a figure less than half of where shares are currently trading. Even the more constructive RBC, which raised its target to $45 from $38 on July 7, only maintained a "Sector Perform" rating, underscoring how limited the bullish conviction is across the Street.
The fundamental backdrop adds further weight. Moderna reported Q1 2026 revenue of $389 million on May 1, a striking 260% jump from $108 million a year earlier—but the top-line surge masked real damage underneath. GAAP EPS came in at a $3.40 loss versus the $3.02 consensus estimate, a $0.38 miss, and the net loss widened to $1.343 billion from $971 million, largely because of a $878 million charge tied to the Arbutus/Genevant litigation settlement. Sequential revenue deterioration adds another layer of concern: the latest reported quarter showed $352 million versus $646 million in the prior quarter, a 45.5% sequential decline. Management maintained 2026 revenue-growth guidance of up to 10%, but projected approximately $3.0 billion in R&D spending and $1.8 billion in cost of sales—an expense structure that keeps profitability a distant prospect.
With second-quarter results scheduled for July 31, investor anxiety is likely to build rather than fade in the days ahead. Consensus estimates call for a $2.00-per-share loss and just $103.1 million in revenue for Q2—a dramatic step-down from Q1 that would further illustrate the lumpy, COVID-cycle-dependent nature of Moderna's revenue base. Beyond the quarterly report, the FDA's decision on the mRNA-1010 flu vaccine remains the next major binary catalyst, carrying the potential to either validate the company's platform diversification story or deal another blow to investor confidence. Against a backdrop of elevated expenses, widening losses, and a valuation that still sits well above what most analysts believe is warranted, the path of least resistance remains lower.
What is the Moderna, Inc. Rating - Should I Sell?
Weiss Ratings assigns MRNA a D- rating. The rating was upgraded on 3/12/2026. Current recommendation is Sell.
Even after that upgrade, the D- sits firmly in Sell territory, and the sub-index breakdown explains why the caution is warranted. Revenue growth of 260.19% is the one undeniable bright spot, reflecting the sharp rebound in Moderna's COVID franchise from a severely depressed base—but that headline figure earns only a Weak Growth Index rating once the full picture is considered, including the sequential collapse in quarterly revenue and the narrow product base generating that growth. The Weak Total Return Index and Weak Volatility Index complete a trio of weak signals that paint a difficult picture for performance-oriented investors: the stock has been exceptionally volatile, and that volatility has not rewarded holders on a sustained basis.
The deeper damage shows up in efficiency and profitability. A profit margin of -143.55% earns the Very Weak Efficiency Index—a figure that reflects a biotech burning through capital on a litigation settlement, clinical development, and a cost structure built for a much larger revenue base than the company currently commands. A forward P/E of -7.00 underscores the point: there are no near-term earnings to anchor valuation, leaving the stock entirely dependent on future pipeline execution and investor sentiment. The Excellent Solvency Index is a genuine positive, indicating Moderna's balance sheet retains enough liquidity to fund operations through this difficult stretch—but solvency alone is not a sufficient foundation for a Buy or Hold argument when losses are widening and execution risk remains high.
Within the Health Care sector, Moderna sits among the weaker names. It is on equal footing with Revolution Medicines, Inc. (RVMD, D-), Natera, Inc. (NTRA, D-), and BeOne Medicines AG (ONC, D-)—a peer group that reflects the broad challenges facing development-stage and pipeline-dependent biotechs in the current environment. Zoetis Inc. (ZTS, D) and Chugai Pharmaceutical Co., Ltd. (CHGCF, D+) carry marginally stronger ratings, highlighting that even within a cautious sector, MRNA ranks at the lower end of the risk spectrum.
About Moderna, Inc.
Moderna, Inc. (MRNA) is a Health Care company built on the promise of messenger RNA as a programmable medicine platform. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company gained global recognition through its COVID-19 vaccine, Spikevax, which remains the commercial anchor of its business. That same mRNA technology now underpins a broad and ambitious pipeline spanning respiratory vaccines, latent viral diseases, oncology, and rare genetic disorders—a diversification strategy designed to reduce the company's dependence on a single product in a post-pandemic market.
On the respiratory side, Moderna's portfolio includes COVID vaccines, an RSV vaccine under the brand mRESVIA, and the mRNA-1010 seasonal influenza candidate that is approaching an FDA decision. The company is also advancing vaccines for cytomegalovirus, Epstein-Barr virus, and HIV, as well as public health programs targeting Zika, Nipah, and Mpox. In oncology, Moderna's lead program—intismeran autogene, developed in collaboration with Merck & Co., Inc.—represents one of the most closely watched personalized cancer vaccine programs in the industry, using mRNA to target individual tumor mutations.
Beyond its pipeline, Moderna maintains a set of strategic partnerships and collaborations that extend its reach across therapeutic areas and geographies, including alliances with Vertex Pharmaceuticals for rare diseases, immatics N.V. for cancer immunology, and OpenAI for computational research. The company's proprietary lipid nanoparticle delivery technology, refined through its COVID vaccine development, represents a durable competitive asset—one that underpins both its existing products and the broader pipeline. However, translating that platform advantage into sustained commercial revenue across multiple indications remains the central challenge for the business.
Investor Outlook
Moderna, Inc. (MRNA) carries a Weiss Rating of D- (Sell), and the combination of widening losses, a sequential revenue decline, and an analyst consensus sitting roughly $14 below the current share price leaves limited margin for error heading into the July 31 Q2 earnings report. Investors should watch both that quarterly print—where consensus expects a $2.00-per-share loss on just $103.1 million in revenue—and the upcoming FDA decision on mRNA-1010, which represents the next meaningful catalyst capable of shifting the narrative in either direction. See full rankings of all D--rated Health Care stocks inside the Weiss Stock Screener.
--